At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating Ipilimumab and Vemurafenib for Melanoma. Completed, enrolled 70 participants across 14 sites.
Detailed Summary
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartSep 2012
Primary CompletionJul 2014
Study CompletionMay 2015
TodayJul 2026
First PostedAug 28, 2012
Enrollment StartSep 13, 2012
Primary CompletionJul 25, 2014
Study CompletionMay 12, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.8 years ago
Interventions
Ipilimumabdrug
Vemurafenibbiological